Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
BUSINESS
Another Global PIII Shuttered for Arcus-Partnered TIGIT Combo: Taiho
Taiho Pharmaceutical said on April 21 that another global PIII study on a combination therapy involving domvanalimab — an anti-TIGIT antibody that it has licensed in Japan from US biotech Arcus Biosciences — was discontinued after failing to show efficacy.…
To read the full story
Related Article
- Global PIII Trial Halted for Arcus-Partnered TIGIT Drug: Taiho
December 16, 2025
- Taiho Seals Trial Pact for Arcus Oncology Meds to Work with Gilead
May 19, 2023
- Taiho Exercises Option to Grab Arcus’ Anti-TIGIT Antibodies
December 1, 2021
BUSINESS
- Taiho Takes Small-Molecule Expertise into ADCs; 3-Payload IND Due This Year
September 14, 2026
- Cuorips Raises 4 Billion Yen to Fund Post-Riheart Pipeline
September 14, 2026
- Boehringer, Medical Society Launch ILD Research Grant Program
September 14, 2026
- Otsuka Steps Up Neuroplastogen Push in Psychiatry
September 14, 2026
- Medipal, JCR Launch Global PI/II of MPS IIIB Therapy
September 14, 2026
Japanese Prime Minister Sanae Takaichi has pledged to respond to the US most-favored-nation (MFN) drug pricing policy to safeguard timely…
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…